Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis. Halder SK, Anumanthan G, Maddula R, Mann J, Chytil A, Gonzalez AL, Washington MK, Moses HL, Beauchamp RD, Datta PK (2006) Cancer Res 66: 6156-66 The murine type II TGF-beta receptor has a coincident embryonic expression and binding preference for TGF-beta 1. Lawler S, Candia AF, Ebner R, Shum L, Lopez AR, Moses HL, Wright CV, Derynck R (1994) Development 120: 165-75 Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Glaser KB, Li J, Aakre ME, Morgan DW, Sheppard G, Stewart KD, Pollock J, Lee P, O'Connor CZ, Anderson SN, Mussatto DJ, Wegner CW, Moses HL (2002) Mol Cancer Ther 1: 759-68 Differential binding of transforming growth factor-beta 1, -beta 2, and -beta 3 by fibroblasts and epithelial cells measured by affinity cross-linking of cell surface receptors. Lyons RM, Miller DA, Graycar JL, Moses HL, Derynck R (1991) Mol Endocrinol 5: 1887-96 Receptor protein-tyrosine phosphatase RPTPmu binds to and dephosphorylates the catenin p120(ctn). Zondag GC, Reynolds AB, Moolenaar WH (2000) J Biol Chem 275: 11264-9 Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL (2001) Mol Biol Cell 12: 27-36 Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species. Samarakoon R, Dobberfuhl AD, Cooley C, Overstreet JM, Patel S, Goldschmeding R, Meldrum KK, Higgins PJ (2013) Cell Signal 25: 2198-209
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.